Business Context and Reporting Period
The filing is Blade Air Mobility, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2024. The source document does not identify Strata Critical Medical, Inc.; investors should verify the company identity. Blade provides passenger air transportation and medical logistics, including human-organ transport, using an asset-light model supported by third-party aircraft operators and proprietary technology.
Blade reports two segments: Passenger, comprising Short Distance and Jet and Other, and Medical, comprising MediMobility Organ Transport. The company is developing its platform for potential future use with electric vertical aircraft.
Financial Performance and Position
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Revenue | $51.5 million | $45.3 million | Up 14% |
| Operating loss | $9.9 million | $12.8 million | Improved $3.0 million |
| Net loss | $4.2 million | $10.2 million | Improved $6.0 million |
| Net loss per share | $0.06 | $0.14 | Improved |
| Adjusted EBITDA | $(3.5) million | $(7.7) million | Improved $4.2 million |
| Flight Profit | $10.1 million | $7.2 million | Up 42% |
| Flight Margin | 19.7% | 15.8% | Up 3.9 points |
| Gross Profit | $5.9 million | $3.2 million | Up $2.6 million |
| Gross Margin | 11.4% | 7.1% | Up 4.3 points |
Medical revenue increased 35% to $36.0 million, driven by new hospital clients, higher activity from existing clients, longer average trip distances, higher revenue per flight hour, and increased ground transportation revenue. Passenger revenue decreased 16% to $15.5 million, including a 30% decline in Jet and Other revenue following the discontinuation of seasonal New York–South Florida by-the-seat jet service.
Cost of revenue increased 9% to $41.4 million but declined to 80% of revenue from 84%. Management attributed the improvement primarily to greater use of dedicated aircraft and higher Medical revenue per flight hour. General and administrative expense increased 6% to $17.2 million, while software development expense declined 40% to $0.7 million and selling and marketing expense declined 18% to $2.1 million.
Medical segment Adjusted EBITDA increased to $4.4 million from $1.9 million, with margin improving to 12% from 7%. Passenger segment Adjusted EBITDA remained negative at $(2.7) million, although it improved from $(3.1) million.
Cash Flow, Liquidity, Debt and Capital Resources
- Cash and cash equivalents were $36.8 million at March 31, 2024, compared with $27.9 million at December 31, 2023.
- Short-term investments were $114.2 million, down from $138.3 million at year-end. These were primarily investment-grade U.S. Treasury securities held to maturity.
- Total liquidity, defined by management as cash and short-term investments, was $151.0 million, compared with $166.1 million at December 31, 2023. Restricted cash was $1.3 million.
- The company reported zero debt and $170.8 million of net working capital.
- Operating cash flow was negative $15.6 million, compared with negative $16.9 million in the prior-year quarter.
- Investing cash flow was positive $24.6 million, primarily reflecting maturities of held-to-maturity investments exceeding purchases.
- Cash, cash equivalents and restricted cash increased by $9.0 million during the quarter to $38.1 million.
- Management stated that existing liquidity should fund current operations for at least the next 12 months and that no additional capital is expected to be needed for the current business plan over that period.
Material Changes Versus the Prior Comparable Period
- Revenue growth was driven by the Medical segment, more than offsetting declines in both Passenger product lines.
- Profitability improved across operating and non-GAAP measures, primarily due to Medical scale, dedicated-aircraft utilization, lower marketing expense, and lower corporate costs.
- The fair value of warrant liabilities declined by $3.5 million, creating non-operating income. Warrant liabilities were $1.5 million at March 31, 2024 versus $5.0 million at December 31, 2023; this benefit is non-cash and market-driven.
- Accounts payable and accrued expenses declined by $13.0 million from year-end, contributing to operating cash use. Management attributed the cash outflow partly to payment of Trinity contingent consideration and the 2023 short-term incentive plan.
- Common shares outstanding increased to 77.1 million at March 31, 2024 from 75.1 million at December 31, 2023, primarily reflecting equity issued for the Trinity earn-out and employee equity activity.
- The board authorized a stock repurchase program of up to $20.0 million on March 20, 2024; the filing does not report repurchases during the quarter.
Guidance, Outlook, Risks and Unusual Items
No formal revenue or earnings guidance is provided in the filing. Management expects near-term net losses while it executes strategic initiatives and identifies seasonality in Passenger demand, historically strongest in the second and third quarters.
On March 11, 2024, Blade agreed to acquire eight fixed-wing aircraft for approximately $21.0 million, funded by approximately $9.3 million of existing prepaid deposits and $11.7 million of cash. Seven aircraft were acquired between April 1 and May 2, 2024; the remaining aircraft was expected to close in subsequent months. The aircraft are intended to support the Medical business.
Remaining capacity-purchase obligations totaled $16.4 million for the remainder of 2024 and $22.5 million for 2025, with certain amounts cancellable upon government-imposed travel restrictions or with notice. Operating lease liabilities totaled $25.5 million, and undiscounted future lease payments were $32.9 million.
Two putative class actions relating to the acquisition of Old Blade were consolidated in April 2024. Plaintiffs allege disclosure and fiduciary-duty violations and seek damages, attorneys’ fees and costs. The company states that the claims lack merit and intends to defend them vigorously.
Material risks include continued losses and negative operating cash flow; reliance on third-party aircraft operators, hospitals, transplant centers and organ procurement organizations; aircraft availability, safety, insurance and fuel costs; competition; weather and geographic concentration; regulatory restrictions; technology and cybersecurity failures; litigation; and uncertainty regarding the certification and commercial adoption of electric vertical aircraft.
Management concluded that disclosure controls and procedures were not effective as of March 31, 2024 because of material weaknesses in IT general controls and revenue-process controls. Remediation was ongoing, with certain revenue controls expected to be implemented by the end of the second quarter and remediation efforts expected to be completed before year-end 2024. The weaknesses will not be considered remediated until controls operate effectively for a sufficient period and testing is completed.
Investor Verification Items
- Verify the issuer identity: the provided filing is for Blade Air Mobility, Inc., not Strata Critical Medical, Inc.
- Assess whether Medical segment growth and improved margins are sustainable, including the effect of newly acquired aircraft and dedicated-aircraft utilization.
- Reconcile reported liquidity with ongoing negative operating cash flow, aircraft acquisition spending, capacity-purchase obligations and the authorized share repurchase program.
- Monitor remediation of the disclosed material weaknesses in IT general controls and revenue controls.
- Evaluate the potential financial and disclosure impact of the consolidated Delaware litigation.
- Separate recurring operating improvement from non-cash warrant-liability gains when assessing profitability.
- Review the completion and funding of the eighth aircraft acquisition and the resulting effect on capital intensity and operating commitments.